LabVantage Recognized as Top Growth and Innovation Leader by Frost & Sullivan in First Annual Global Life Sciences LIMS Report and Radar
LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services, including purpose-built LIMS solutions that allow labs to go live faster and at a lower total cost, today celebrated receiving global recognition as a top growth and innovation leader by Frost & Sullivan in the firm's first-ever Frost RadarTM: Global Laboratory Information Management Systems (LIMS) for the Life Sciences Industry 2023 Report. LabVantage earned the No. 1 ranking for growth on the Radar by securing high scores for its consistent growth trajectory, high market share, ability to capitalize on new growth opportunities, and commitment to continued innovation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231019604433/en/
LabVantage Solutions earned the top, outermost spot on the Frost Radar™, an independent comparative analytical benchmarking system, for its combined growth potential and ability to drive innovation. (Graphic: Business Wire)
The Frost Radar, created by growth advisory and analytics firm Frost & Sullivan, is an independent comparative analytical benchmarking tool that maps organizations and their LIMS solutions to identify top leaders in growth and innovation. Its growth index measures five parameters, including market share, revenue growth, growth pipeline, vision and strategy alignment, and sales and marketing effectiveness. The Radar’s innovation index evaluates scalability, research and development, product portfolio, leverage of long-term opportunities and new business models, and customer alignment. Using these indices, Frost & Sullivan benchmarked 120 LIMS solution vendors for the life sciences industry and represented the top 12 on the Radar as best-in-class solutions based on their features, capabilities, data integrity, interoperability, and informatics and analytics applications.
"Frost Radar Growth and Innovation leaders like LabVantage stand out because of their continuous innovation, comprehensive LIMS functionalities for life sciences companies, and regional commercial capabilities. They are instrumental in advancing the industry into the future,” said Piyush Bansal, Global Program Leader, at Frost & Sullivan. “The laboratory ecosystem is complex and requires tailored solutions for specific needs. LabVantage offers customers a best-in-class LIMS solution, reflected in its consistent growth and strong portfolio pipeline. Given its proven ability to scale continually, it has the potential to set an industry benchmark."
The Frost & Sullivan report recognizes LabVantage’s comprehensive product portfolio, the company’s hybrid approach of leveraging internal R&D and external collaborations to access new technology, and significant investments in artificial intelligence (AI) and Natural Language Processing (NLP) to adeptly manage both scientific and unstructured data. The report marks LabVantage as a ‘Company to Action’ and a primary driver of competitive intensity in its growth environment, noting the company’s significant future growth potential, best practices in the industry, and ability to amplify its customer value proposition. The report also honors LabVantage’s partnership potential and reputation as a significant value provider to customers, investors, value chain partners and prospective talent.
“We pioneered the integration of LIMS, ELN, LES, and SDMS into a comprehensive platform for lab informatics, continuously improving it in collaboration with our customers to provide valuable business intelligence. We are delighted to have our approach validated by such a respected industry voice as Frost & Sullivan,” said Mikael Hagstroem, Chief Executive Officer at LabVantage Solutions. “The Frost Radar report reinforces the need in the life science industry for a platform that delivers an integrated approach to solving the challenges of managing critical scientific data end-to-end, from R&D to manufacturing to quality control.”
LabVantage has strengthened its technological capabilities in the past year by acquiring Biomax Informatics and unveiling AILANI, a tool that synergizes semantic modeling, ontologies, linguistics, and AI algorithms and revolutionizes query-based research in various databases. Demonstrating commitment to leveraging growth prospects in emerging Latin America and increasing its footprint throughout the region, the company recently made two professional service acquisitions in Brazil and Colombia.
To see the Frost & Sullivan summary report, click here. For more information on LabVantage and its LIMS solutions, visit www.labvantage.com or email info@labvantage.com.
About LabVantage Solutions
A recognized leader in enterprise laboratory software solutions, LabVantage Solutions dedicates itself to improving customer outcomes by transforming data into knowledge. The LabVantage informatics platform is highly configurable, integrated across a common architecture, and 100% browser-based to support hundreds of concurrent users. Deployed on-premise, via the cloud, or SaaS, it seamlessly interfaces with instruments and other enterprise systems – enabling true digital transformation. The platform consists of the most modern laboratory information management system (LIMS) available, integrated electronic laboratory notebook (ELN), laboratory execution system (LES), scientific data management system (SDMS), and advanced analytics; and, for healthcare settings, a laboratory information system (LIS). We support more than 1500 global customer sites in the life sciences, pharmaceutical, medical device, biobank, food & beverage, consumer packaged goods, oil & gas, genetics/diagnostics, forensic, and healthcare industries. Headquartered in Somerset, NJ, with global offices, LabVantage has offered its comprehensive portfolio of products and services to enable customers to innovate faster in the R&D cycle, improve manufactured product quality, achieve accurate record-keeping, and comply with regulatory requirements for four decades. For more information, visit labvantage.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231019604433/en/
Contact information
Media Contact:
Charya Wickremasinghe, Ph.D.
Brandwidth Solutions
cwickremasinghe@brandwidthsolutions.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Reply Announces the Jury for the First AI Music Contest: Finalists Will Perform Live on Stage at Kappa FuturFestival in Turin23.5.2025 11:05:00 EEST | Press release
Reply, an international group specialized in the creation of new business models enabled by Artificial Intelligence and driven by a strong culture of innovation, is expanding its creative experimentation initiatives this year with the launch of the AI Music Contest. Organised in collaboration with Kappa FuturFestival, one of Europe’s leading electronic music festivals, the competition is open to creatives and innovators who use AI technologies to explore new forms of integration between sound and visuals. It aims to enhance the expressive potential of artificial intelligence in live performances. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250523250887/en/ The jury members include prominent figures such as Seth Troxler and DJ Tennis, who are renowned DJs and producers known for their pioneering use of AI in live performances. Also on the panel is Albertino, a DJ, radio host and the artistic director of Radio m2o. Alongsid
Kioxia Holdings Corporation Wins IPO of the Year Award in the Equity Category at the DealWatch Awards 202423.5.2025 10:00:00 EEST | Press release
Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced that it had won the IPO of the Year award in the Equity category at the DealWatch Awards 2024, organized by DealWatch, the most authoritative source of real-time intelligence for deal activity within Japan's capital markets. The award was presented at a ceremony held on May 20. The DealWatch Awards recognize outstanding issuers of bonds or equities in the Japanese capital market, as well as Japanese issuers who have conducted offerings overseas, and the securities firms that manage these transactions. The awards for 2024 comprised six categories: Overall, Bonds, Local Government Bonds, Cross-Border Bonds, Sustainable Finance, and Equity. Selection is based on criteria such as the appropriateness of pricing in the issuance market, price formation after transition to the trading market, contribution to the development of capital markets, and innovative efforts, with the awards designed to promot
Generix Named in the 2025 Gartner® Magic Quadrant™ for Warehouse Management Systems (WMS) for the Seventh Consecutive Year23.5.2025 10:00:00 EEST | Press release
Generix, a global business software company offering an expansive portfolio of SaaS solutions for supply chain, finance, commerce, and B2B integration, today announces it has been recognized by Gartner in the 2025 Gartner® Magic Quadrant™ for Warehouse Management Systems (WMS). This is the seventh consecutive year that Generix has been recognized for its portfolio of WMS Solutions. Designed to scale as supply chain operations grow from simple to complex flows, Generix WMS and Solochain WMS are currently in more than 2,000 warehouses globally. “We are honored to be recognized in the Gartner® Magic Quadrant™ WMS for the seventh consecutive year. Generix continues its commitment to providing WMS for every warehousing need at a global scale. With our two recognized WMS solutions, Generix WMS and Solochain WMS, we continue to innovate to better serve customer needs with the introduction of industry game-changing AI use-cases such as resource planning and computer vision,” said Si-Mohamed Sa
NuORDER by Lightspeed and Mandatory Renew Partnership to Power Hybrid Commerce at the Third Edition of the Copenhagen Event23.5.2025 10:00:00 EEST | Press release
Mandatory and NuORDER by Lightspeed, the industry’s leading B2B commerce platform, are joining forces for the third consecutive time to power the digital extension of Mandatory’s in-person trade event, taking place August 5–7 in Copenhagen. This renewed partnership reflects the continued momentum behind hybrid commerce—where physical and digital trade intersect to create smarter, more flexible buying experiences. As the Nordic fashion ecosystem expands with energy and innovation, Mandatory has become a magnet for trendsetting brands and forward-looking retailers. On NuORDER’s wholesale platform, buyer activity from Nordic-region retailers surged by 39.4% year over year in Q1 2025 (January to March). "Retailers in the Nordic region have been quick to adopt digital tools to enhance the efficiency of their buying processes. The increase in buyer activity on the NuORDER platform early this year clearly indicates a growing market demand and a renewed engagement within the industry," said Ch
Curatis discloses Corticorelin as active substance of C-PTBE-0123.5.2025 08:00:00 EEST | Press release
An epidemiological market study commissioned by Curatis Holding AG (SIX:CURN, “Curatis”) shows that the target patient group is substantially larger than previous estimates. In the US alone, over 150,000 patients suffer from peritumoral brain edema in association with malignant tumors. In previous clinical studies, human corticorelin (C-PTBE-01), demonstrated significant benefits in the treatment of PTBE. “The prospect of developing a potential blockbuster drug with that can contribute significantly to the quality of life of many patients, combined with the potential of maintaining the efficacy of immunotherapies for these patients, is very motivating and exciting,” said Dr. Roland Rutschmann, Curatis CEO. Key statements Corticorelin (hCRH), a 41 amino acid endogenous polypeptide, has demonstrated the ability to positively impact the blood-brain barrier after a disruption due to the underlying malignant tumor. Curatis intends to develop corticorelin to treat PTBE in primary and metasta
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom